ASCO Genitourinary Cancers Symposium
Meet with our team at ASCO GU
Posters and Presentations
Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig).
Time
11:30 AM – 1:00 PM PST
Abstract / Poster Number
186 H15
Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).
Time
11:30 AM – 1:00 PM PST
Abstract / Poster Number
196 J4
Primary sarcoma of prostate: A genomic landscape study.
Time
11:30 AM – 1:00 PM PST
Abstract / Poster Number
181 H10
FGFR3 mutated (FGFR3mut+) urothelial carcinoma of bladder (UCB) or upper tract (UTUC): A comparative genomic landscape study.
Time
7:40 AM – 8:45 AM PST
Abstract / Poster Number
540
Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before radical cystectomy (RC).
Time
11:30 AM – 1:00 PM PST
Abstract / Poster Number
653 J17
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC).
Time
11:30 AM – 1:00 PM PST
Abstract / Poster Number
610 G16
Urachal (U) and non-urachal (NU) adenocarcinomas (adenoCA) of the bladder: A comparative comprehensive genomic profiling (CGP) study.
Time
7:40 AM – 8:45 AM PST
Abstract / Poster Number
535
Prognostic value of circulating tumor DNA fraction (TF) for patients with metastatic renal cell carcinoma (mRCC).
Time
7:00 AM – 8:10 AM PST
Abstract / Poster number
455 J16
Fanconi anemia complementation group C (FANCC) gene association with hereditary and sporadic renal tumors (RT).
Time
7:00 AM – 8:10 AM PST
Abstract / Poster Number
450 J11
Malignant epithelioid angiomyolipoma (eAML)/PEComa of the kidney: A genomic landscape study.
Time
7:00 AM – 8:10 AM PST
Abstract / Poster Number
451 J12
Comprehensive genomic profiling (CGP) of squamous cell carcinoma of unknown primary (SCCUP) presenting with inguinal, pelvic, and retroperitoneal (I/P/RP) metastases.
Time
7:00 AM – 8:10 AM PST
Abstract / Poster Number
7 E6
Relevant Publications
Prostate Cancer
Unique Spectrum of Activating BRAF Alterations in Prostate Cancer.
Authors
Chehrazi-Raffle A, Tukachinsky H, Toye E, Sivakumar S, Schrock AB, Bergom HE, et al.
Journal
Clin Cancer Res. 2023;29(19):3948-57.
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
Authors
Graf RP, Fisher V, Weberpals J, Gjoerup O, Tierno MB, Huang RSP, et al.
Journal
JAMA Netw Open. 2022;5(3):e225394.
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations.
Authors
Eule CJ, Flaig TW, Wong K, Graf R, Lam ET
Journal
Prostate Cancer Prostatic Dis. 2023;26(1):188 93.
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
Authors
Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, et al.
Journal
JCO Precis Oncol. 2022;6:e2200195.
Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens.
Authors
Hiemenz MC, Graf RP, Schiavone K, Harries L, Oxnard GR, Ross JS, et al.
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.
Authors
Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, et al.
Journal
Clin Cancer Res. 2023;29(1):81-91.
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Authors
Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, et al.
Journal
Clin Cancer Res. 2022;28(22):4917-25.
Bladder Cancer
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
Authors
Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, et al.
Journal
Nat Rev Urol. 2023;20(7):406-19.
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
Authors
Necchi A, Basile G, Gibb EA, Raggi D, Calareso G, de Padua TC, et al.
Journal
BJU Int. 2023.
Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss.
Authors
Basin MF, Bratslavsky G, Nahhas N, Basnet A, Goldberg H, Necchi A, et al.
Journal
Urol Oncol. 2023;41(2):109 e15- e22.
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
Authors
Powles T, Young A, Nimeiri H, Madison RW, Fine A, Zollinger DR, et al.
Journal
Front Oncol. 2023;13:1221718.
HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
Authors
Ghelani GH, Zerdan MB, Jacob J, Spiess PE, Li R, Necchi A, et al.
Journal
Urol Oncol. 2023;41(12):486 e15- e23.
Emerging targets in upper tract urothelial carcinomas: the TERT gene.
Authors
Ortiz Restrepo A, Ross JS, Spiess PE, Necchi A, Li R, Garcia-Perdomo HA.
Journal
Can J Urol. 2022;29(6):11378-83.
Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial.
Authors
Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, et al.
Journal
Clin Cancer Res. 2022;28(23):5107-14.
Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry.
Authors
Peak T, Spiess PE, Li R, Grivas P, Necchi A, Pavlick D, et al.
Journal
Oncologist. 2023;28(10):e910-e20.
Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
Authors
Bou Zerdan M, Bratslavsky G, Jacob J, Ross J, Huang R, Basnet A.
Journal
Mol Diagn Ther. 2023;27(4):475-85.
Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma.
Authors
Graf RP, Fisher V, Huang RSP, Hamdani O, Gjoerup OV, Stanke J, et al.
Journal
JCO Precis Oncol. 2022;6:e2200121.
Kidney Cancer
Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
Authors
Hacking SM, Pavlick D, Wang Y, Carneiro BA, Mullally M, Lu S, et al.
Journal
Oncologist. 2023;28(7):e508-e19.
Relevant Pan/Multi-tumor Cancer Publications
Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays.
Authors
Wang D, Elenbaas B, Murugesan K, Shah K, Montesion M, Gounaris I, et al.
Journal
NPJ Precis Oncol. 2023;7(1):103.
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.
Authors
Reichert ZR, Morgan TM, Li G, Castellanos E, Snow T, Dall'Olio FG, et al.
Journal
Ann Oncol. 2023;34(1):111-20.
Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors.
Authors
Jardim DLF, Millis SZ, Ross JS, Lippman S, Ali SM, Kurzrock R.
Journal
Oncologist. 2023;28(2):e82-e91.
Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Authors
Murugesan K, Necchi A, Burn TC, Gjoerup O, Greenstein R, Krook M, et al.
Journal
ESMO Open. 2022;7(6):100641.
Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing.
Authors
Tung N, Dougherty KC, Gatof ES, DeLeonardis K, Hogan L, Tukachinsky H, et al.
Journal
NPJ Precis Oncol. 2023;7(1):76.
Immunotherapy in the Treatment of Localized Genitourinary Cancers.
Authors
Necchi A, Faltas BM, Slovin SF, Meeks JJ, Pal SK, Schwartz LH, et al.
Journal
JAMA Oncol. 2023;9(10):1447-54.
Not all TMB assays are the same: Clinical validity of robust algorithmic germline filtering.
Authors
Huang RSP, Graf RP, Oxnard GR.
Journal
Cancer Cell. 2023;41(5):819-20.
Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples.
Authors
Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, et al.
Journal
JCO Precis Oncol. 2022;6:e2200261.
Influencing Best Practices for Genomic and Germline Testing in Urology.
Authors
Shore N, Scott TA, Srivastava A, Grove R, Thompson A, Tierno MB, et al.
Journal
Urol Pract. 2023;10(6):648-54.
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
Authors
Moore JA, Chen KT, Madison R, Newberg JY, Fleischmann Z, Wang S, et al.
Journal
JCO Precis Oncol. 2023;7:e2300093.
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.
Authors
Heilmann AM, Riess JW, McLaughlin-Drubin M, Huang RSP, Hjulstrom M, Creeden J, et al.
Journal
Oncologist. 2023.